In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


John Hodgson

Data Editor, Pharma

Cambridge, U.K
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better.
Set Alert for Articles By John Hodgson

Latest From John Hodgson

Stock Scan February 2018: Wet But Above Water

The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.

European Life Sciences Start-Ups Maintain Early Investor Allure

Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.

Europe Financing

Pay, Patriots And The Art of Promise: What Results Season Taught Us

Most of the biggest pharmaceutical companies that pay taxes in Europe or North America have told the world how they got on in 2017. So what, other than the corrective value of financial performance minutiae, did we learn?

Business Strategies Biosimilars

Stock Scan January 2018: Hope Sprung Eternal

Commercial Companies

Stock Scan Q4 2017 – Q3 Reporting Chops $70bn From Pharma

Big pharma stocks lost value overall in the fourth quarter of 2017 despite good performances from Asian companies and Kåre Schultz taking over at Teva.

Growth Financing

2017 Pharma Sales: A New Global Order

As the reality of annual results arrive, Scrip predicts how the top of the pharma league table is likely to change.

Sales & Earnings Growth
See All